 Delcath Systems, Inc. DCTH, an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a single-institution retrospective study conducted by University Hospital of Tubingen UHT in Germany on the use of the Delcath Hepatic CHEMOSAT Delivery System to treat patients with metastatic ocular melanoma with liver metastases were published in the journal Cancer Imaging. 